eteplirsen

Aaron Kesselheim

Biotech

Harvard's Kesselheim quits AdComm over FDA's Aduhelm approval

Kesselheim’s departure means the FDA has lost one-third of the permanent voting members of the committee in the days since the approval.

Nick Paul Taylor Jun 11, 2021 4:47am

FDA sign

FDA expert lashes out at 'worrisome' Sarepta approval in JAMA

Oct 25, 2016 4:39am

John Jenkins

FDA new drugs director slams Sarepta approval as ‘NOT a good model’

Oct 20, 2016 6:13am